[144] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) filed a Form 144 on 06/26/2025 disclosing a proposed sale of 398 common shares by Ericka von Kaeppler & Denis von Kaeppler (joint tenants). The shares were originally acquired on 12/28/2021 through an open-market purchase for cash. Morgan Stanley Smith Barney LLC is listed as the executing broker and the transaction is slated for NASDAQ execution on or after 06/26/2025. At the filing date, BridgeBio had 189,880,720 shares outstanding, making the contemplated sale approximately 0.0002 % of total shares.

The filing also reports prior insider activity within the last three months: Hannah Valantine sold a total of 17,168 shares (four identical entries of 4,292 shares) on 06/10/2025, generating aggregate gross proceeds of roughly $686,363. No adverse information was acknowledged by the filer, and the customary Rule 144 representations were signed.

Overall, the notice documents routine insider selling of a very small stake with negligible impact on the company’s share structure.

Positive

• Sale represents only 0.0002 % of outstanding shares, indicating negligible dilution or supply impact.

Negative

• Continued insider sales disclosed (17,168 shares sold on 06/10/2025 plus 398 planned), which could weigh on investor sentiment despite small size.

Insights

Securities Analyst

TL;DR: Minor Form 144 signals negligible dilution; continued insider selling trend worth monitoring.

The 398-share planned disposition equates to less than 0.001 % of BridgeBio’s float and should not meaningfully affect supply-demand dynamics. However, the filing confirms that insiders—specifically Hannah Valantine earlier and now the Von Kaeppler family—are monetising holdings. While the dollar value is immaterial, consecutive filings can influence sentiment if they persist. From a compliance perspective, all disclosures and Rule 144 representations appear complete.

Portfolio Manager

TL;DR: Transaction is immaterial; monitor for pattern rather than single event.

With a market value of just $17,562, the sale will not impact liquidity or fundamentals. The larger data point is cumulative insider selling (~17 k shares recently), which, although still small, may prompt a qualitative review of insider activity versus corporate milestones. Absent other catalysts, the filing is not impactful for portfolio positioning.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855608
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BRIDGEBIO PHARMA, INC.
SEC File Number	001-38959
Address of Issuer	3160 Porter Drive Suite 250 Palo Alto CALIFORNIA 94304
Phone	(650) 391-9740
Name of Person for Whose Account the Securities are To Be Sold	ERICKA VON KAEPPLER & DENIS VON KAEPPLER JT TEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	account owners are spouse and daughter of bod

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	398	17562.27	189880720	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/28/2021	Open Market Purchase	Open Market			398	12/28/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
HANNAH A VALANTINE 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	06/10/2025	4292	171680.00

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Valantine Hannah
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did BridgeBio Pharma (BBIO) disclose in its Form 144 filed on 06/26/2025?

The company reported a planned sale of 398 common shares by Ericka & Denis von Kaeppler through Morgan Stanley.

How large is the proposed sale relative to BridgeBio’s total shares outstanding?

It equals roughly 0.0002 % of the 189,880,720 shares outstanding, indicating minimal impact.

When were the shares originally acquired?

The shares were acquired on 12/28/2021 via an open-market purchase paid in cash.

Were there any other insider sales noted in the filing?

Yes. Hannah Valantine sold 17,168 shares on 06/10/2025 for total proceeds of about $686,363.

What is the broker handling the planned transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.